Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

S. Karim; K. Ding; P. Bradbury; P. Ellis; N. Mittman; X. Xiaoqun Sun; M. Millward; G. Liu; S. Sun; M. R. Stockler; V. Cohen; N. Blais; R. Sangha; M. Boyer; R. Sasidharan; C. Lee; F. A. Shepherd; G. Goss; L. Seymour; N. B. Leighl

Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26

S. Karim, K. Ding, P. Bradbury, P. Ellis, N. Mittman, X. Xiaoqun Sun, M. Millward, G. Liu, S. Sun, M. R. Stockler, V. Cohen, N. Blais, R. Sangha, M. Boyer, R. Sasidharan, C. Lee, F. A. Shepherd, G. Goss, L. Seymour, N. B. Leighl

Research output: Contribution to journal › Abstract/Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Annals of Oncology
Volume	28
Publication status	Published - Sept 2017
Externally published	Yes
Event	42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain Duration: 8 Sept 2017 → 12 Sept 2017

Cite this

Karim, S., Ding, K., Bradbury, P., Ellis, P., Mittman, N., Sun, X. X., Millward, M., Liu, G., Sun, S., Stockler, M. R., Cohen, V., Blais, N., Sangha, R., Boyer, M., Sasidharan, R., Lee, C., Shepherd, F. A., Goss, G., Seymour, L., & Leighl, N. B. (2017). Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26. Annals of Oncology, 28.

@article{9603639fb19b44c1a2fe2acf68d397a1,

title = "Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC: CCTG BR.26",

author = "S. Karim and K. Ding and P. Bradbury and P. Ellis and N. Mittman and Sun, {X. Xiaoqun} and M. Millward and G. Liu and S. Sun and Stockler, {M. R.} and V. Cohen and N. Blais and R. Sangha and M. Boyer and R. Sasidharan and C. Lee and Shepherd, {F. A.} and G. Goss and L. Seymour and Leighl, {N. B.}",

year = "2017",

month = sep,

language = "English",

volume = "28",

journal = "Annals of Oncology",

issn = "0923-7534",

publisher = "Oxford University Press",

note = "42nd European-Society-for-Medical-Oncology Congress (ESMO) ; Conference date: 08-09-2017 Through 12-09-2017",

}

TY - JOUR

T1 - Costs of dacomitinib versus placebo in pretreated unselected patients (pts) with advanced NSCLC

T2 - 42nd European-Society-for-Medical-Oncology Congress (ESMO)

AU - Karim, S.

AU - Ding, K.

AU - Bradbury, P.

AU - Ellis, P.

AU - Mittman, N.

AU - Sun, X. Xiaoqun

AU - Millward, M.

AU - Liu, G.

AU - Sun, S.

AU - Stockler, M. R.

AU - Cohen, V.

AU - Blais, N.

AU - Sangha, R.

AU - Boyer, M.

AU - Sasidharan, R.

AU - Lee, C.

AU - Shepherd, F. A.

AU - Goss, G.

AU - Seymour, L.

AU - Leighl, N. B.

PY - 2017/9

Y1 - 2017/9

M3 - Abstract/Meeting Abstract

SN - 0923-7534

VL - 28

JO - Annals of Oncology

JF - Annals of Oncology

Y2 - 8 September 2017 through 12 September 2017

ER -